Invion Limited (ASX:IVX) Reports Positive Phase I/II Skin Cancer Trial Results
Clinical Trial Results
Invion Limited reported no adverse events in its Phase I/II non-melanoma skin cancer trial, treating the first six patients with INV043. Early indications show a reduction in lesion size after a single treatment cycle, and patients experienced no pain during treatment.
Theragnostic Potential
INV043 demonstrated potential as a theragnostic, with cancer cells fluorescing under violet light, aiding in accurate cancer identification and removal.
Next Steps
The trial will progress to Part 2, focusing on dose optimisation. Additionally, safety data will inform the upcoming Phase I/II anogenital trial in partnership with Peter MacCallum Cancer Centre.
Executive Comments
Prof Thian Chew, Executive Chair and CEO, stated, “We are very pleased with the safety profile of INV043 and look forward to exploring other elements that may help optimise the dose regime. It is also exciting to see how clearly and easily INV043 can ‘illuminate’ the cancers. The results set us up for the next stages of our clinical program, including the planned Phase I/II anogenital trial as well as the next part of the NMNC trial, where we are seeking to further demonstrate the safety of INV043 and to better optimise the treatment regime in the next group of patients.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
